S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
PRI   130.63 (+0.14%)
NFLX   310.48 (-0.39%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
Log in

Rexahn Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:REXN)

$2.00
-0.08 (-3.85 %)
(As of 11/22/2019 04:00 PM ET)
Today's Range
$2.00
Now: $2.00
$2.15
50-Day Range
$1.65
MA: $1.88
$2.30
52-Week Range
$1.56
Now: $2.00
$19.80
Volume40,300 shs
Average Volume90,508 shs
Market Capitalization$8.04 million
P/E RatioN/A
Dividend YieldN/A
Beta1.08
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REXN
CUSIPN/A
Phone240-268-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.92 per share

Profitability

Net Income$-14,370,000.00

Miscellaneous

Employees10
Market Cap$8.04 million
Next Earnings Date11/25/2019 (Estimated)
OptionableOptionable

Receive REXN News and Ratings via Email

Sign-up to receive the latest news and ratings for REXN and its competitors with MarketBeat's FREE daily newsletter.


Rexahn Pharmaceuticals (NASDAQ:REXN) Frequently Asked Questions

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the NASDAQ under the ticker symbol "REXN."

When did Rexahn Pharmaceuticals' stock split? How did Rexahn Pharmaceuticals' stock split work?

Shares of Rexahn Pharmaceuticals reverse split on the morning of Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 11th 2019. An investor that had 100 shares of Rexahn Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) announced its earnings results on Wednesday, August, 7th. The company reported ($0.61) EPS for the quarter, beating the Zacks' consensus estimate of ($0.95) by $0.34. View Rexahn Pharmaceuticals' Earnings History.

When is Rexahn Pharmaceuticals' next earnings date?

Rexahn Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 25th 2019. View Earnings Estimates for Rexahn Pharmaceuticals.

What price target have analysts set for REXN?

3 brokers have issued twelve-month target prices for Rexahn Pharmaceuticals' stock. Their forecasts range from $23.00 to $23.00. On average, they anticipate Rexahn Pharmaceuticals' stock price to reach $23.00 in the next year. This suggests a possible upside of 1,050.0% from the stock's current price. View Analyst Price Targets for Rexahn Pharmaceuticals.

What is the consensus analysts' recommendation for Rexahn Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rexahn Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Rexahn Pharmaceuticals.

What are Wall Street analysts saying about Rexahn Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rexahn Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. " (10/29/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $10 price target. The majority of contribution to our valuation comes from RX-3117, which represents over 65% of our price target. Remaining valuation comes from RX-5902 (Supinoxin) for triple negative breast cancer. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (3/8/2019)

Has Rexahn Pharmaceuticals been receiving favorable news coverage?

News coverage about REXN stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rexahn Pharmaceuticals earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Rexahn Pharmaceuticals.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 39,000 shares, a drop of 30.1% from the September 30th total of 55,800 shares. Based on an average daily volume of 55,500 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.0% of the shares of the stock are short sold. View Rexahn Pharmaceuticals' Current Options Chain.

Who are some of Rexahn Pharmaceuticals' key competitors?

What other stocks do shareholders of Rexahn Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SLS International (SLS), CytRx (CYTR), Synergy Pharmaceuticals (SGYP), AcelRx Pharmaceuticals (ACRX), Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX) and Novavax (NVAX).

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the folowing people:
  • Douglas J. Swirsky, President, CEO, CFO, Secretary & Director
  • D J Kim, Vice President, Head-Research & Development
  • Lisa M. Nolan, Chief Business Officer

How do I buy shares of Rexahn Pharmaceuticals?

Shares of REXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of REXN stock can currently be purchased for approximately $2.00.

How big of a company is Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals has a market capitalization of $8.04 million. The company earns $-14,370,000.00 in net income (profit) each year or ($5.28) on an earnings per share basis. Rexahn Pharmaceuticals employs 10 workers across the globe.View Additional Information About Rexahn Pharmaceuticals.

What is Rexahn Pharmaceuticals' official website?

The official website for Rexahn Pharmaceuticals is http://www.rexahn.com/.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company can be reached via phone at 240-268-5300 or via email at [email protected]


MarketBeat Community Rating for Rexahn Pharmaceuticals (NASDAQ REXN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  153
MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe REXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel